We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Biologics inch toward cholesterol-lowering market.
- Authors
Garber, Ken
- Abstract
The article discusses the potential of monoclonal antibody (mAb) targeting proprotein convertase subtilisin/kexin type 9 (PCSK9) for treating hypercholesterolemia. Regeneron Pharmaceuticals' phase 2 trial data on this antibody revealed a 65% mean drop in low-density lipoprotein (LDL) levels in individuals with familial hypercholesterolemia after just three treatments of high dose. A list of other biologics targeting PCSK9 for hypercholesterolemia is also provided.
- Subjects
HYPERCHOLESTEREMIA treatment; MONOCLONAL antibodies; PROPROTEIN convertases; REGENERON Pharmaceuticals Inc.; LOW density lipoprotein absorption &; adsorption
- Publication
Nature Biotechnology, 2012, Vol 30, Issue 4, p302
- ISSN
1087-0156
- Publication type
Article
- DOI
10.1038/nbt0412-302